| 49th week of 2011 patent applcation highlights part 47 |
| Patent application number | Title | Published |
|---|
| 20110301175 | 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases. | 2011-12-08 |
| 20110301176 | IMIDAZOTHIAZOLE DERIVATIVES HAVING PROLINE RING STRUCTURE - There is provided compounds that inhibit interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. Compounds include imidazothiazole derivatives that can inhibit interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity. | 2011-12-08 |
| 20110301177 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative - The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule. | 2011-12-08 |
| 20110301178 | PYRAZINYL CARBOXAMIDES AS FUNGICIDES - This present disclosure is related to the field of pyrazine carboxamides and their derivatives and the use of these compounds as fungicides. | 2011-12-08 |
| 20110301179 | NAPHTHAMIDES AS ANTICANCER AGENTS - A compound (particularly useful for inhibiting cancer) according to formula I: | 2011-12-08 |
| 20110301180 | Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration - It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner. | 2011-12-08 |
| 20110301181 | halogen-substituted compounds - The invention relates to compounds of the general formula (I), | 2011-12-08 |
| 20110301182 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor - The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for improving glycemic control in type 2 diabetes patients with inadequate glycemic control despite metformin therapy. | 2011-12-08 |
| 20110301183 | CHEMICAL SYNTHESIS OF A HIGHLY POTENT EPOTHILONE - A highly active synthetic epothilone compound whose activity exceeds that of either epothilone EpoA or EpoB when assayed as a cytotoxic agent against a cancer cell line is disclosed as is a pharmaceutical composition containing the synthetic epothilone. | 2011-12-08 |
| 20110301184 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR - A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use. | 2011-12-08 |
| 20110301185 | CANCER TREATMENT METHOD - The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound. | 2011-12-08 |
| 20110301186 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE - This invention is directed to methods and compositions for the treatment of cardiovascular disorders. Specifically, the invention is directed to compositions comprising vitamin E, statins and/or glutathione peroxidase mimetics; methods of treating diabetic patients expressing the Hp-2-2 haptoglobin genotype; a method of inhibiting or suppressing a cardiovascular disorder in a diabetic subject, treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype; and methods of treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype. | 2011-12-08 |
| 20110301187 | BIS [O-(14-BENZOYLACONINE-8-YL)] ESTERS - The present invention concerns novel compounds having the structure (I). Another object of the invention is the use of compounds (I) for the fabrication of a medicament which is used for the treatment of tumour diseases. | 2011-12-08 |
| 20110301188 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents - This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent. | 2011-12-08 |
| 20110301189 | STABLE PHARMACEUTICAL COMPOSITIONS OF RAPAMYCIN ESTERS - A stable pharmaceutical compositions of Rapamycin Esters, in particular Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid that is free of antioxidants and a process of preparing the same. | 2011-12-08 |
| 20110301190 | POLYMORPHIC FORMS OF A GABAA AGONIST - The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms. | 2011-12-08 |
| 20110301191 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS - Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment. | 2011-12-08 |
| 20110301192 | Inhibitors of Cyclin Kinase Inhibitor p21 - The present invention provides compounds that inhibit cyclin kinase inhibitor p21, such as compounds of formula I. The present invention also provides compositions including compounds of Formula I and a pharmaceutically acceptable excipient. In addition, the present invention provides methods of inhibiting cyclin kinase inhibitor p21 and of treating cancer. | 2011-12-08 |
| 20110301193 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT - Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR. | 2011-12-08 |
| 20110301194 | Method for Determining Treatment Efficacy - The present invention provides a method for determining the efficacy of a c-Met inhibitor in treating a cell proliferative disorder, comprising: a) administering to a subject in need thereof a therapeutically effective amount of the c-Met inhibitor, or a pharmaceutically acceptable salt, prodrug or metabolite thereof, either alone or in combination with a therapeutically effective amount of a second anti-proliferative agent; and b) measuring the concentration of hepatocyte growth factor (HGF) in the serum from the subject, wherein if the concentration of serum HGF does not decrease, or if the concentration of serum HGF increases, the c-Met inhibitor is efficacious in treating the cell proliferative disorder. | 2011-12-08 |
| 20110301195 | TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE - The present invention relates to compound 1, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound 1 and methods of using the compositions in the treatment of proliferative disorders. | 2011-12-08 |
| 20110301196 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE - The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds. | 2011-12-08 |
| 20110301197 | Bis(difluoromethyl)pyrazoles as Fungicides - Bis(difluoromethyl)pyrazole derivatives of the formula (I) | 2011-12-08 |
| 20110301198 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide. | 2011-12-08 |
| 20110301199 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof in patients who have been treated with a DNA methyltransferase inhibitor by a combination of ezatiostat or a salt thereof and lenalidomide. | 2011-12-08 |
| 20110301200 | THYROID RECEPTOR LIGANDS - The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta (TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them. | 2011-12-08 |
| 20110301201 | DABIGATRAN FOR PERCUTANEOUS INTERVENTIONAL CARDIAC CATHETERISATION - The invention relates to a new use of dabigatran etexilate of formula (I) optionally in the form of the pharmaceutically acceptable salts thereof, and new medicament formulations which may be used for this purpose. | 2011-12-08 |
| 20110301202 | SPLA2 INHIBITOR CONJUGATE COMPOUNDS AND METHODS OF USE - The present application provides a novel set of compounds comprising a sPLA | 2011-12-08 |
| 20110301203 | CHEMICAL COMPOUNDS - This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds. | 2011-12-08 |
| 20110301204 | ADMINISTRATION REGIME FOR NITROCATECHOLS - The present invention relates to novel dosage regimens for compounds of formula I: where the substituents are as defined in the specification. | 2011-12-08 |
| 20110301205 | ISOXAZOLE DERIVATIVES FOR USE AS FUNGICIDES - The present invention relates to isoxazole compounds of formula (I) having fungicidal activity, to agricultural compositions comprising them, and to the use of said compounds and compositions in agriculture for the control of microbial pests, particularly fungal pests, on plants. | 2011-12-08 |
| 20110301206 | SYNERGISTIC PRESERVATIVE BLENDS - The present invention is a preservative formulation which includes a combination of at least two (2) compounds having bactericidal and/or fungicidal properties wherein the at least two (2) compounds is selected from the group consisting of methylisothiazolinone/piroctone olamine; caprylyl glycol/dehydroacetic acid; undecanol/dehydroacetic acid and lauryl alcohol/sorbic acid. The invention also includes preparations including such combination as well as a method of using the combination to reduce bacterial and fungal load of preparations. | 2011-12-08 |
| 20110301207 | METHODS AND SUSTAINED RELEASE NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA - An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night. | 2011-12-08 |
| 20110301208 | VIRAL AND FUNGAL INHIBITORS - Novel classes of viral and fungal inhibitors are disclosed. These compounds are useful in treating, preventing, and/or ameliorating viral infections such as, for example, Hepatitis C Virus, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus, and fungal infections such as, for example, candidiasis. | 2011-12-08 |
| 20110301209 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS - Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject. | 2011-12-08 |
| 20110301210 | USE OF PRAMIPEXOLE TO TREAT AMYOTROPHIC LATERAL SCLEROSIS - The present invention is directed to compositions comprising pramipexole and the use of such compositions to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As shown in FIG. | 2011-12-08 |
| 20110301211 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 2011-12-08 |
| 20110301212 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH PROTOONCOGENE PRODUCTS - The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof. | 2011-12-08 |
| 20110301213 | USE OF PILOCARPINE FOR HYPOPTYALISM TREATMENT - A method of treating hypoptyalism in a subject is provided. The method includes administering to the subject a pharmaceutical composition that includes pilocarpine and a bioadhesive polymer. The composition dissolves sublingually in the mouth of the subject and adheres to mucous tissues in the buccopharyngeal cavity. The pilocarpine then dissolves and binds to muscarine receptors present in cells of the subject's salivary glands, endobuccal submucous glands and submaxillary glands, is then absorbed by the cells thereby stimulating the glands to produce saliva. | 2011-12-08 |
| 20110301214 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL - Disclosed herein is a pharmaceutical composition comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol and methods of using the composition to treat chronic pain. | 2011-12-08 |
| 20110301215 | INHIBITORS OF PLASMA KALLIKREIN - The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment. | 2011-12-08 |
| 20110301216 | ANTICANCER AND ANTIMICROBIAL COMPOUNDS FROM ANTARCTIC EXTREMOPHILIC MICROORGANSIMS - The present disclosure describes the isolation of extremophilic microorganisms from the Lakes of Schirmacher Oasis located in the East Antarctic Dronning Maud Land. The isolated organisms were characterized and certain pigments produced by these microorganisms were isolated. The present disclosure teaches that the isolated pigments exhibit anticancer and antimicrobial properties and can be used as new therapies for the treatment and prevention of cancer and microbially-mediated diseases. | 2011-12-08 |
| 20110301217 | Selective Glycosidase Inhibitors and Uses Thereof - The application relates to an immoalditol compound for selectively inhibiting glycosidases, a prodrug thereof and a pharmaceutical composition comprising the compound or the prodrug The application also relates to the use of the immoalditol compound for treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc Such diseases and disorders include neurodegenerative diseases, tauopathy, cancers, and cardiac disorders | 2011-12-08 |
| 20110301218 | MODIFIED snRNAs FOR USE IN THERAPY - The invention relates to a nucleic acid encoding a small nuclear RNA (snRNA), which snRNA is modified so that it contains sequence capable of hybridizing with the 5′ and 3′ splice site junctions and an exonic splicing enhancer of an exon of a pre-mRNA, so that the exon sequence is skipped during the splicing process that converts the pre-mRNA in the mature mRNA. The nucleic acid, the modified snRNA and vectors incorporating the nucleic acid may be used in the therapy, in particular in the treatment of muscular dystrophies. | 2011-12-08 |
| 20110301219 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism. | 2011-12-08 |
| 20110301220 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism. | 2011-12-08 |
| 20110301221 | DIAGNOSIS, PROGNOSIS AND TREATMENT OF GLIOBLASTOMA MULTIFORME - The present invention in one aspect relates generally to the identification, provision and use of a plurality of biomarkers to provide risk assessment of a subject having glioblastoma multiforme, and products and processes related thereto. In one aspect, a novel plurality of biomarkers as described herein is provided to determine a risk of glioblastoma multiforme. In another aspect, a novel plurality of biomarkers as described herein is provided to diagnose a subject having glioblastoma multiforme. In yet another aspect are methods for treating a subject having glioblastoma multiforme by administering one or more therapeutic regimens for glioblastoma multiforme. In yet another aspect are nucleic acid arrays comprising nucleic acid probes that hybridize to one or more glioblastoma multiforme genes. | 2011-12-08 |
| 20110301222 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER - The present invention provides methods of sensitizing cancer cells to docetaxel and inhibiting the growth of various tumors by employing a modified eIF-4E antisense oligonucleotide and docetaxel in combination. | 2011-12-08 |
| 20110301223 | COMPOSITIONS AND METHODS FOR INSECTICIDAL CONTROL OF STINKBUGS - Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a Pentatomidae plant pest or a | 2011-12-08 |
| 20110301224 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene. | 2011-12-08 |
| 20110301225 | Compounds and Methods for Reducing the Recruitment and/or Migration of Polymorphonuclear Cells - A therapeutically effective amount of an oligonucleotide is capable of influencing the properties and behaviour of polymorphonuclear cells, e.g. suppressing endothelial adhesion and transmigration of said cells, and through this mechanism reduce the recruitment and/or migration of polymorphonuclear cells to a site of inflammation. | 2011-12-08 |
| 20110301226 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC NEOPLASIA - The present invention provides compositions and methods featuring miR-26 microRNA polynucleotides for the diagnosis, treatment or prevention of hepatic neoplasia. | 2011-12-08 |
| 20110301227 | PROLIFERATION-ASSOCIATED MODULATION OF THE SPLICING OF THE INTEGRIN ALPHA 6 ISOFORMS - This application relates to the use of agents such as expression vectors and nucleic acids encoding integrins α6A or α6B as well as antibodies specific for those integrins which are capable of modulating the ratio between the B and A isoforms of the α6 integrin in the treatment of diseases associated with an altered proliferation rate, such as cancer. The application also relates to the use of the ratio between the B and A isoforms of the α6 integrin in the diagnosis of diseases associated with an altered proliferation rate. | 2011-12-08 |
| 20110301228 | GENE THERAPY VECTOR FOR TREATMENT OF STEROID GLAUCOMA - The presently disclosed subject matter provides an inducible vector comprising a therapeutic gene. In some embodiments a method is provided for treating steroid glaucoma. In some embodiments a method is provided for preventing elevated intraocular pressure in a subject receiving steroid treatment. In some embodiments a method is provided for reversing elevated intraocular pressure in a subject receiving steroid treatment. In some embodiments a steroid treatment method is provided. Also provided are pharmaceutical compositions comprising an inducible vector. | 2011-12-08 |
| 20110301229 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery. | 2011-12-08 |
| 20110301230 | GENE CARRIER - Disclosed is a gene carrier composed of a hydrogen-bonding polymer having a polymer chain with hydrogen-bonding sites formed on the polymer chain, in which the polymer chain has a conformation similar to the conformation of a nucleic acid, and particularly, the polymer chain has helix parameters similar to the helix parameters of a nucleic acid of a helix structure. In a preferred embodiment, the hydrogen-bonding polymer is composed of β-1,3-glucan such as schizophyllan. The carrier can be expected to be applied as a vector and a separator for nucleic acids because it is capable of interacting with a nucleic acid to form a complex with the nucleic acid and thus carrying the nucleic acid. | 2011-12-08 |
| 20110301231 | LIPASE INHIBITING COMPOSITION - Pharmaceutical compositions that contain a lipase inhibitor having a melting point ≧37° C., a sucrose fatty acid ester wherein the sucrose fatty acid ester is a mono-, di-, tri- or tetra-ester, and optionally one or more pharmaceutically acceptable excipients, are useful for treatment of obesity. | 2011-12-08 |
| 20110301232 | PROCESS OF EXTRACTING PROCYANIDINS BY ALKALINE HYDROLYSIS - A process of extracting procyanidins by alkaline hydrolysis. In particular, a procyanidin-containing material, pomace or residue is treated with an alkali, such as sodium or potassium hydroxide, for a predetermined amount of time and at a predetermined temperature to release procyanidins bound to polysaccharides and/or proteins of the cell wall or depolymerize polymeric procyanidins. After the procyanidins are released by alkaline hydrolysis, the extracts are acidified to obtain a pH level where the procyanidins do not degrade. The process of extracting procyanidins may be utilized to estimate the total amount of bound procyanidins in a plant material, enhance the bioavailability of beneficial procyanidins monomers and/or to treat the residue remaining after conventional solvent extraction for increased procyanidin extraction. | 2011-12-08 |
| 20110301233 | Novel Polyisoprenylated Benzophenone Derivatives from Garcinia paucinervis - Novel polyisoprenylated benzophenone derivatives isolated from the plant | 2011-12-08 |
| 20110301234 | FORMULATIONS OF LADOSTIGIL TARTRATE - The invention relates to a pharmaceutical composition of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water. The composition is typically in a solid oral form which upon administration to a human subject provides a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL. | 2011-12-08 |
| 20110301235 | ORGANOSELENIUM COMPOUNDS AND USES THEREOF - Provided herein are organoselenium compounds and pharmaceutical compositions thereof. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders using the compounds and pharmaceutical compositions provided herein. | 2011-12-08 |
| 20110301236 | HeLa-C3 Apoptosis Inducer from Garcinia paucinervis - A novel compound isolated from the plant | 2011-12-08 |
| 20110301237 | METHODS AND COMPOSITIONS FOR NOVEL LIQUID CRYSTAL DELIVERY SYSTEMS - Methods of making a liquid crystal mixture essentially comprised of at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at least one alkali reactant. The resultant mixture includes at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at least one salt of said fatty acid ester or fatty acid. The resultant mixture exhibits enhanced stability and aqueous solubility of fatty acids and fatty acid esters. When medium chain fatty acid monoglycerides are used in the method, the resultant mixture exhibits antimicrobial efficacy. | 2011-12-08 |
| 20110301238 | SEIZURE RELATED DISORDERS AND THERAPEUTIC METHODS THEREOF - Methods of treating seizure disorders by administration of a therapeutically effective amount of at least one precursor of propionyl-CoA in the absence of a ketogenic diet are provided. The present invention particularly applies to administration of triglyceride oils and preferably, triheptanoin and derivatives thereof. | 2011-12-08 |
| 20110301239 | USE OF NOVEL LIPID MEDIATORS TO INHIBIT ANGIOGENESIS - The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA or DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. | 2011-12-08 |
| 20110301240 | CONDITIONING COMPOSITION - The present invention is directed to a composition for the conditioning of a dental mineralized surface and/or a dental implant and/or for increasing the hydrophilicity of a dental implant having a metal containing surface. The composition comprises EDTA in a concentration of 21-55% by weight and having a pH of 9.0 or above. The high pH of the composition allows more EDTA to be dissolved and the composition is useful for the conditioning of mineralized dental surfaces and/or surfaces of dental implants. The composition of the invention may thus be used for the conditioning of mineralized dental surfaces and dental implant surfaces in order to remove e.g. biofilm, debris, bacteria, bacterial toxins etc and/or for increasing the hydrophilicity of an implant having a metallic surface. The invention is also directed to a kit comprising the composition of the invention and a device to apply the composition to a surface in need of conditioning. | 2011-12-08 |
| 20110301241 | NEW HALO ACTIVE AROMATIC SULFONAMIDE ORGANIC COMPOUNDS AND USES THEREFOR - Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. This disclosure deals with the use of halo active aromatic sulfonamide organic compounds as odor control and/or biocidal agents in a cleaning solution for use with bovines and other dairy animals. | 2011-12-08 |
| 20110301242 | Inhibitors of Cathepsin S for Prevention or Treatment of Obesity-Associated Disorders - The present invention relates to methods (and pharmaceutical compositions) for treating and/or preventing for obesity associated disorders, particularly related to a deregulation of glucose homeostasis, by administrating Cathepsin S inhibitors. The invention also relates to methods for diagnosing insulin resistance and glucose tolerance by measuring Cathepsin S levels in a biological sample obtained from a subject. | 2011-12-08 |
| 20110301243 | NOVEL METHOD - The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent. | 2011-12-08 |
| 20110301244 | FAST ACTING NARATRIPTAN COMPOSITION - The present invention relates to pharmaceutical compositions containing Naratriptan, a compound selected from the group consisting of 2-HPOD, 2-HPHM, 4-PPED, 4-BPED and 2-PPED, and optionally, a pharmaceutically acceptable excipient. | 2011-12-08 |
| 20110301245 | (R)-2-(3,4-DIMETHOXYPHENOL)-2-ISOPROPYL-6-AZAHEPTANITRIL FORMULAITONS, ANDTHE USE OF SUCH FORMULATIONS IN THE TREATMENT OF CONDITIONS MEDIATED BY THE SEROTONIN TRANSPORTER - Methods comprising administering compositions comprising therapeutically effective amounts of the (R)-isomer of 2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats or prevents at least one condition having serotonin transporter activity in a subject in need thereof, and releases the (R)-isomer of 2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril, a derivative thereof, or a pharmaceutically acceptable salt thereof to exhibit an activity on the serotonin transporter. | 2011-12-08 |
| 20110301246 | ANTIFUNGAL COMPOSITIONS FOR INHIBITING GROWTH OF WOOD DECAY FUNGI AND USE THEREOF - The present invention is related to an antifungal composition for the inhibition of wood decay caused by wood rot fungi. The invention further comprises a method for the inhibition of wood decay with gallates. | 2011-12-08 |
| 20110301247 | COSMETIC PRODUCT CONTAINING FILM-FORMING POLYMER - Disclosed herein is a cosmetic product which contains a polymer having the repeating unit represented by the following formula (1) or (2): | 2011-12-08 |
| 20110301248 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 2011-12-08 |
| 20110301249 | STEM CELL ENHANCED PROTEIN PRODUCTS AND USES THEROF - Methods for producing in-vitro cultured protein products that are enhanced with stem cells are disclosed. In-vitro cultured protein product compositions produced by said methods are also disclosed. The present invention also discloses methods of providing nutrients to an animal by feeding said animal with said in-vitro cultured protein products. | 2011-12-08 |
| 20110301250 | Composition for Treating Dry Eye and Related Methods of Manufacture and Methods of Use - The present invention is directed to a composition for treating dry eye comprising, in one embodiment, carboxymethylcellulose and a polyol. Such compositions have been found to alleviate the symptoms of dry eye and remain in the eye for a long period of time. | 2011-12-08 |
| 20110301251 | DISPERSIBLE CARBON NANOTUBES AND METHOD FOR PREPARING SAME - Dispersible single-walled and multi-walled carbon nanotubes (CNTs) are prepared by dissolving surfactants in water to form a solution; adding carbon nanotubes to the solution to form a mixture; sonicating and agitating the mixture to form a carbon-nanotube/water dispersion; centrifuging the dispersion to remove un-dispersed carbon nanotubes and impurities; repeatedly freezing and heating the CNT dispersion; and, sublimating water in the CNT dispersion by freezing and evacuating the dispersion to obtain carbon nanotubes coated with surfactant. The carbon nanotubes prepared by the method of the invention are dry, amphiphilic, and surfactant-coated powders that can be dispersed in both aqueous and organic solvents to form stable and uniform dispersions having a high concentration of carbon nanotubes. | 2011-12-08 |
| 20110301252 | Process for Synthesis of Methanol - A process for synthesis of methanol, where make-up syngas is reacted in a synthesis loop ( | 2011-12-08 |
| 20110301253 | METHOD OF OPERATING A FLUID BED REACTOR - Method of operating a three-phase slurry reactor includes feeding at a low level at least one gaseous reactant into a vertically extending slurry body of solid particles suspended in a suspension liquid, the slurry body being contained in at least two vertically extending shafts housed within a common reactor shell, each shaft being divided into a plurality of vertically extending channels at least some of which are in slurry flow communication and the slurry body being present in at least some of the channels. The gaseous reactant is allowed to react as it passes upwardly through the slurry body present in at least some of the channels of the shafts, thereby to form a non-gaseous and/or a gaseous product. Gaseous product, if present, and/or unreacted gaseous reactant is allowed to disengage from the slurry body in a head space above the slurry body. | 2011-12-08 |
| 20110301254 | Process for preparing organic silicon compounds - The invention provides a process for preparing organically modified siloxanes by catalysed reaction of siloxanes having at least one SiH group with a compound having a double bond. | 2011-12-08 |
| 20110301255 | EPOXIDE-BASED STRUCTURAL FOAM COMPRISING THERMOPLASTIC POLYURETHANES - Disclosed is a thermally expandable and curable material containing: a) at least one epoxide prepolymer; b) at least one heat-activated curing agent for the prepolymer; c) at least one foaming agent; and d) at least one thermoplastic, non-reactive polyurethane selected from among polyurethanes containing a polyester chain. Also disclosed are the use of such a material for stiffening or reinforcing components as well as an extruded or injection-molded article made of such a material. | 2011-12-08 |
| 20110301256 | FINE PARTICLE-DISPERSED POLYOL COMPOSITION, METHOD FOR PRODUCING POLYMER POLYOL, AND METHOD FOR PRODUCING POLYURETHANE RESIN - A polyol composition comprising a polyol (a) and resin fine particles (b) dispersed in the polyol (a), and a method for producing the polyol composition are provided, wherein the resin fine particles (b) are particles such that an arithmetic standard deviation by volume of a particle size distribution of the particles, derived from respective values in 85 divisions of a range of 0.020 to 2000 μm determined by a laser diffraction/scattering particle size distribution analyzer, is not more than 0.6. A resin fine particle-dispersed polyol composition that, even if the resin particles dispersed in the polyol have a small particle diameter, allows the production of a polyurethane resin having an excellent mechanical strength such as elongation at break, and a method for producing the same, are provided. | 2011-12-08 |
| 20110301257 | FINE PARTICLE-DISPERSED POLYOL COMPOSITION, METHOD FOR PRODUCING POLYMER POLYOL, AND METHOD FOR PRODUCING POLYURETHANE RESIN - A polyol composition comprising a polyol (a) and resin fine particles (b) dispersed in the polyol (a), and a method for producing the polyol composition are provided, wherein the resin fine particles (b) are particles such that an arithmetic standard deviation by volume of a particle size distribution of the particles, derived from respective values in 85 divisions of a range of 0.020 to 2000 μm determined by a laser diffraction/scattering particle size distribution analyzer, is not more than 0.6. A resin fine particle-dispersed polyol composition that, even if the resin particles dispersed in the polyol have a small particle diameter, allows the production of a polyurethane resin having an excellent mechanical strength such as elongation at break, and a method for producing the same, are provided. | 2011-12-08 |
| 20110301258 | Non-Dripping Flame Retarding Masterbatch, Composition and Process for Preparing the Same and Flame Retarding Article Containing the Same - Disclosed herein are methods for preparing non-dripping flame retarding masterbatches and filamentous non-dripping flame retarding materials. First, an admixture including a flame retardant, a crosslinking agent, a thermoplastic polymer, and a dispersing agent is prepared, and then a crosslinking initiator is added into the admixture to form a composition which is then compounded and pelletized to obtain the non-dripping flame retarding masterbatch. The resultant non-dripping flame retarding masterbatch is suitable for use in a spinning process to obtain filamentous non-dripping flame retarding materials. | 2011-12-08 |
| 20110301259 | TEMPORAL INTRALUMINAL STENT, METHODS OF MAKING AND USING - A biodegradable polymer stent with radiopacity and a method of making and using a stent with enhanced mechanical strength and/or controlled degradation for use in a bodily lumen is described. | 2011-12-08 |
| 20110301260 | HIGH-STRENGTH GLUE STICK FORMULATION - A high-strength glue stick formulation that includes water; a defoamer; a bactericide; an oil; polyvinylpyrrolidone; a plurality of polyurethane dispersions; dipropylene glycol n-butyl ether; sodium stearate; casein; sodium hydroxide; and at least one adhesion promoter. | 2011-12-08 |
| 20110301261 | Silane-Sulfide Chain End Modified Elastomeric Polymers - A chain end modified polymer comprising the reaction product of a living anionic elastomeric polymer and a silane-sulfide modifier A preferred class of modifiers includes compounds represented by the formula: (RO)x(R) | 2011-12-08 |
| 20110301262 | PROCESS FOR PRODUCING COMPATIBILIZED POLYMER BLENDS - A process is provided for producing a compatibilized polymeric blend. A first thermoplastic polymer and a reactive moiety are provided to a progressive melt kneading apparatus. The reactive moiety comprises a first reactive group capable of reacting with the first thermoplastic polymer but not a second polymer and a second reactive group capable of reacting with the second polymer but not the first polymer. The first thermoplastic polymer and the reactive moiety are then melt kneaded so that the first reactive group reacts with the first thermoplastic polymer and the second reactive group is grafted to the first thermoplastic polymer, forming a molten self-compatibilizer. A molten second polymer is then provided. The molten self-compatibilizer is melt kneaded with the molten second polymer so that the second reactive group reacts with the second polymer to form a compatibilized polymeric blend. Also provided are articles formed from the compatibilized polymer blend. | 2011-12-08 |
| 20110301263 | GAP-FILLING ADHESIVE OF STONE - An adhesive for filling in gaps between stones, the adhesive including at least 100 weight parts of an unsaturated polyester resin suitable for air-drying, between 1 and 5 weight parts of hydrogenated castor oil, between 0 and 60 weight parts of micron silica, and between 1 and 15 weight parts of an anti-shrinking agent. The adhesive overcomes the disadvantages of conventional marble glue, such as, poor air-drying property, poor shrinkage resistance, and poor permeability. The adhesive of the invention has good permeability, strong shrinkage resistance, and high brightness after being polished, and is not sticky after curing. The invention solves the difficulty of gap-filling of stone by providing a new category of marble glue. | 2011-12-08 |
| 20110301264 | TWO COMPONENT CURABLE COMPOSITIONS - A two component reactive composition is described, each component, before they are mixed together, contains a filler having thin platelet structure, e.g. a nanoclay, and a further filler that interacts with the platelets. The individual components can have a filler loading that makes them flowable and therefore the components can readily be mixed together for ready dispensing. When the components are mixed thoroughly together, the resulting resin may have a viscosity higher than that of the individual components. The loading of the filler is preferably chosen so that the resulting blended resin is capable of being applied on to a vertical surface without experiencing significant slump. The viscosity of the mixed material can be up to 5 to 10 times or more than that of the individual components before mixing. The composition can be used in adhesives, modelling pastes, coatings, sealants, putties, mastics, stopping compounds, caulking materials, encapsulants and surface coatings. | 2011-12-08 |
| 20110301265 | METHOD OF IMPROVING SCRATCH RESISTANCE AND RELATED PRODUCTS AND USES - The present invention relates to methods of improving the scratch resistance of plastics materials and products made from them, such as articles in the automotive industry e.g. for the interior of automobiles, as well as the use of certain additives for that purpose and related invention embodiments. The improving comprises adding a friction modifier, and in addition a grafted polymer and a fatty acid amide, to a rubber modified polyolefin composition used as polymer substrate for the articles. | 2011-12-08 |
| 20110301266 | FLAME RETARDANT RESIN COMPOSITION AND MOLDED ARTICLE THEREOF - A flame retardant resin composition which has high flame retardancy, excellent heat resistance and physical properties and is obtained from a plant-derived raw material and a molded article thereof. | 2011-12-08 |
| 20110301267 | PLASTISOLS CONTAINING GLYCEROL ESTERS AS PLASTICIZERS - Plastisols and organosols are provided that include plasticizers that include mono-, di- and triesters of glycerol. The plasticizers are good solvators for polyvinyl chloride and impart low plastisol and organosol viscosities. | 2011-12-08 |
| 20110301268 | POLYPROPYLENE RESIN COMPOSITION - A polypropylene resin composition, comprising (A) 51 to 99% by weight of a propylene polymer having a melt flow rate of 10 to 200 g/10 minutes, and containing 0.1 to 40% by weight of an ethylene unit and/or α-olefin unit having 4 to 10 carbon atoms and 60 to 99.9% by weight of a propylene unit, (B) 1 to 49% by weight of an ethylene polymer having density of 0.85 to 0.93 g/cm | 2011-12-08 |
| 20110301269 | Method for Forming Anti-Reflective Coating - A method of forming an antireflective coating on an electronic device comprising (A) applying to an electronic device an ARC composition comprising (i) a silsesquioxane resin having the formula (PhSiO | 2011-12-08 |
| 20110301270 | DISPERSION OF PARTICLES OF RUTILE TITANIUM OXIDE, PROCESS FOR PRODUCING THE SAME, AND USE OF THE SAME - The invention provides a dispersion of particles of rutile titanium oxide wherein the particles of rutile titanium oxide have a D50 in a range of 1 to 15 nm and a D90 of 40 nm or less in particle size distribution as determined by a dynamic light scattering method; a specific surface area in a range of 120 to 180 m | 2011-12-08 |
| 20110301271 | TWO-LIQUID TYPE URETHANE PAINT COMPOSITION - Disclosed is a two-liquid type urethane paint composition having a main agent which includes a hydroxyl group-containing resin (A), a hydrolyzable ester compound (B) and an alcohol-based solvent (C); and a curing agent which includes a polyisocyanate compound (D). The composition is made by mixing together the main agent and the curing agent, wherein the (B) component and the (C) component are included in the main agent in amounts from 2 to 35 parts by mass as effective component of the hydrolyzable ester compound (B) and from 2 to 10 parts by mass of the alcohol-based solvent (C) per 100 parts by mass of solid fraction of the hydroxyl group-containing resin (A), and the hydroxyl groups of the hydroxyl group-containing resin (A) and the functional groups of the polyisocyanate compound (D) are mixed in proportions of from 0.5 to 1.5 as the mol ratio of NCO/OH. | 2011-12-08 |
| 20110301272 | PREPARATION OF ALUMINUM PHOSPHATE OR POLYPHOSPHATE PARTICLES - A process for the preparation of amorphous aluminum phosphate or polyphosphate-based pigment by reacting aluminum phosphate and sodium aluminate is provided. The amorphous aluminum phosphate or polyphosphate is characterized by a skeletal density of less than 2.50 grams per cubic centimeter and a phosphorus to aluminum mole ratio of greater than 0.8. In one embodiment, the composition is useful in paints as a substitute for titanium dioxide. | 2011-12-08 |
| 20110301273 | PIGMENT GRANULES - Pigment granules including a support material which is coated with one or more flake-form effect pigments by means of an adhesion promoter. The effect pigments may be, for example, pearlescent pigments, interference pigments, metal-effect pigments, multilayered pigments having one or more transparent, semi-transparent or opaque layers, goniochromatic pigments, holographic pigments, coated BiOCL flakes, uncoated BiOCl flakes, and LCP pigments, and mixtures thereof. A process for the production of pigment granules includes mixing one or more flake-form effect pigments, a support material, at least one adhesion promoter, and optionally one or more additives simultaneously or successively with one another. The pigment granules may be used for the pigmenting of application media, in particular paints, plasters, coatings, powder coatings, plastics, and in particular as scatter and effect granules, for example for the decoration of wallcoverings. The pigment granules may additionally include one or more additives and assistants. | 2011-12-08 |
| 20110301274 | POWER AND/OR TELECOMMUNICATIONS CABLE HAVING IMPROVED FIRE-RETARDANT PROPERTIES - A method of preparation for a layer of material for use with a power and/or telecommunications cable includes mixing a composition including a thermoplastic polymer matrix and a phenolic resin. The phenolic resin is selected from the group consisting of novolac phenol-formaldehyde resins and novolac cyanate ester resins. The phenolic resin is hardened within the thermoplastic polymer matrix to obtain nodules of hardened phenolic resin dispersed throughout the material. | 2011-12-08 |
